Is glucagon-like peptide-1 (GLP-1) receptor agonist (RA) use associated with a major adverse cardiovascular and cerebrovascular events (MACCE) in patients with monoclonal gammopathy of undetermined significance and type 2 diabetes without prior cardiovascular disease? The gene discussed is GCG; the disease is monoclonal gammopathy.